Physician profile
Alberto Santiago Cornier
NPI 1285763144
$394,465.78
in general payments reported to CMS, 2019-2025
18 companies · $61K in 2025
The $61K reported for 2025 was more than what 96% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150K · 2020: $14K · 2021: $11K · 2022: $48K · 2023: $36K · 2024: $74K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $143K · Travel and Lodging: $13K · Consulting Fee: $9,095 · Food and Beverage: $5,074 · Honoraria: $575 · Education: $35.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $142,709.88 |
| Travel and Lodging | $13,447.19 |
| Consulting Fee | $9,095.00 |
| Food and Beverage | $5,074.16 |
| Honoraria | $575.00 |
| Education | $35.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $150,044.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114,318.79 | 2020-2025 | Elaprase, Vpriv, Takhzyro |
| Genzyme Corporation | $110,465.25 | 2019-2025 | |
| Sarepta Therapeutics, INC. | $10,354.14 | 2025 | Elevidys |
| Acadia Pharmaceuticals INC | $2,892.36 | 2024-2025 | Daybue |
| Cycle Pharmaceuticals INC | $2,513.73 | 2019-2021 | |
| Chiesi USA, INC. | $1,465.04 | 2025 | Elfabrio |
| Ptc Therapeutics, INC. | $1,447.72 | 2025 | Sephience |
| Biogen, INC. | $245.36 | 2021-2023 | Spinraza |
| Biomarin Pharmaceutical INC. | $147.53 | 2019-2022 | |
| Pbg Puerto Rico LLC | $120.03 | 2021-2025 | |
| Genentech, INC. | $107.42 | 2023 | Evrysdi |
| Novartis Pharmaceuticals Corporation | $100.64 | 2023 | |
| Glaxosmithkline, LLC. | $97.09 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $90.00 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer Pharmaceuticals LLC | $20.44 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $18.32 | 2023 | Imcivree |
| Amicus Therapeutics, INC. | $17.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Santiago Cornier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.